URGN logo

UroGen Pharma Community

NasdaqGM:URGN Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

Community Investing Ideas

URGN logo
UroGen Pharma

FDA Approval And Expanding Pipeline Will Advance Uro-Oncology

Key Takeaways Imminent launch of UGN-102 and demographic trends are set to drive substantial revenue and market expansion for UroGen Pharma. Diversification of pipeline assets and favorable clinical outcomes enhance stability, pricing power, and reduce reliance on a single product.
View narrative
US$34.38
FV
48.4% undervalued intrinsic discount
66.11%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
19 days ago author updated this narrative